On Sept. 5, the FDA announced an import alert and green list for glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredient (API) manufacturers. The FDA included manufacturers on the green list ...
The FDA released a warning letter sent to Chinese API maker Qinhuangdao Zizhu Pharmaceutical in April that outlined data integrity problems at the company’s Hebei province facility following an ...
The prices for active pharmaceuticals ingredients (API) will recover in FY27 due to the implementation of minimum import price (MIP) starting from 29 January 2026 and China’s withdrawal value-added ...
In a significant regulatory development aimed at controlling substandard imports, the Government of India has imposed price-based import restriction on sulfadiazine API, a key active pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results